Create Free Account

By creating account you will get access to hot stocks & personalised emails

Compumedics Ltd

Healthcare AU CMP

0.25AUD
-0.01(3.85%)

Last update at 2024-05-02T03:00:00Z

Day Range

0.240.25
LowHigh

52 Week Range

0.150.45
LowHigh

Financials

Income Statement

Balancesheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2023-06-30 2022-06-30 2021-06-30 2020-06-30 2019-06-30
Type yearly yearly yearly yearly yearly
Date 2023-06-30 2022-06-30 2021-06-30 2020-06-30 2019-06-30
Income before tax -6.71900M 1.70M 0.78M -7.50300M 5.07M
Minority interest - - - - -
Net income -6.12200M 1.36M 1.00M -5.83800M 3.99M
Selling general administrative 6.41M 5.64M 6.12M 5.93M 6.42M
Selling and marketing expenses 13.25M 9.48M 8.26M 9.00M 8.47M
Gross profit 21.59M 19.29M 19.16M 18.01M 24.75M
Reconciled depreciation 1.01M 1.21M 1.46M 1.66M 0.43M
Ebit -2.97900M 2.10M -0.35100M -1.08600M 5.33M
Ebitda -1.96600M 2.61M 1.11M 0.58M 5.88M
Depreciation and amortization 1.01M 0.51M 1.46M 1.66M 0.55M
Non operating income net other - - - - -
Operating income -3.01900M 0.99M 0.96M -0.39800M 5.33M
Other operating expenses -7.35400M 0.36M -1.47800M -8.03800M 37.51M
Interest expense 0.65M 0.40M 0.33M 0.42M 0.26M
Tax provision -0.59700M 0.34M -0.22200M -1.66500M 1.07M
Interest income 0.61M 0.23M 1.14M 0.42M 0.26M
Net interest income -0.65200M -0.40100M -0.33000M -0.42000M -0.26100M
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense -0.59700M 0.34M -0.22200M -1.66500M 1.08M
Total revenue 42.41M 37.76M 35.74M 35.07M 41.51M
Total operating expenses 26.14M 19.69M 18.76M 18.77M 20.76M
Cost of revenue 20.82M 18.46M 16.58M 17.06M 16.75M
Total other income expense net -2.53300M 1.99M 0.71M -6.32700M -0.26100M
Discontinued operations - - - - -
Net income from continuing ops -6.12200M 1.36M 1.00M -5.83800M 4.02M
Net income applicable to common shares -6.12200M 1.36M 1.00M -5.83800M 4.02M
Preferred stock and other adjustments - - - - -
Breakdown 2023-06-30 2022-06-30 2021-06-30 2020-06-30 2019-06-30
Type yearly yearly yearly yearly yearly
Date 2023-06-30 2022-06-30 2021-06-30 2020-06-30 2019-06-30
Total assets 41.18M 41.49M 38.55M 35.53M 38.66M
Intangible assets 6.24M 6.45M 4.08M 2.78M 6.79M
Earning assets - - - - -
Other current assets 2.43M 2.35M 2.47M 1.05M 1.84M
Total liab 22.89M 17.90M 16.39M 13.73M 11.34M
Total stockholder equity 18.29M 23.59M 22.16M 21.79M 27.32M
Deferred long term liab 6.24M 6.45M 4.08M 2.78M 6.79M
Other current liab 4.26M 3.51M 3.15M 2.93M 2.86M
Common stock 35.65M 35.65M 35.65M 35.65M 35.65M
Capital stock 35.65M 35.65M 35.65M 35.65M 35.65M
Retained earnings -17.79100M -11.66900M -13.02600M -13.90200M -8.09200M
Other liab 0.14M 0.20M 0.29M 0.45M 1.13M
Good will - - - - -
Other assets 1.10M 6.95M 4.90M 3.56M 6.79M
Cash 3.80M 7.08M 6.77M 6.41M 4.60M
Cash and equivalents - 7.08M - - 4.60M
Total current liabilities 21.19M 17.32M 15.35M 12.44M 10.19M
Current deferred revenue 2.69M 1.92M 1.75M 1.72M 1.38M
Net debt 5.67M -0.74700M -0.95000M -1.61300M -3.00500M
Short term debt 7.91M 5.95M 5.07M 3.95M 1.57M
Short long term debt 7.22M 5.80M 4.41M 3.05M 1.56M
Short long term debt total 9.47M 6.33M 5.82M 4.80M 1.59M
Other stockholder equity -17.86300M -23.98500M -22.62800M -21.63000M 0.01M
Property plant equipment 3.62M 1.21M 1.71M 3.08M 1.65M
Total current assets 29.52M 33.33M 31.93M 28.89M 30.21M
Long term investments 0.70M - - - -
Net tangible assets 18.29M 23.59M 22.16M 21.79M 27.32M
Short term investments - - - - -
Net receivables 12.53M 14.12M 13.01M 12.60M 15.98M
Long term debt 0.20M 0.38M 0.59M 0.01M 0.02M
Inventory 10.69M 9.71M 9.68M 8.83M 7.80M
Accounts payable 6.33M 5.94M 5.38M 3.83M 4.39M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income 0.43M -0.39400M -0.47300M 0.04M -0.25800M
Additional paid in capital - - - - -
Common stock total equity - - - 35.65M 35.65M
Preferred stock total equity - - - - -
Retained earnings total equity - - - - -
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other - -1.21300M -1.71100M -3.08300M -0.78100M
Deferred long term asset charges - - - - -
Non current assets total 11.66M 8.16M 6.61M 6.64M 8.45M
Capital lease obligations 2.04M 0.15M 0.82M 1.74M 0.04M
Long term debt total 1.56M 0.38M 0.75M 0.85M 0.02M
Breakdown 2023-06-30 2022-06-30 2021-06-30 2020-06-30 2019-06-30
Type yearly yearly yearly yearly yearly
Date 2023-06-30 2022-06-30 2021-06-30 2020-06-30 2019-06-30
Investments -4.40800M -2.95900M -1.84300M -4.23300M -4.28600M
Change to liabilities 0.49M 0.92M 1.40M -1.68800M 0.22M
Total cashflows from investing activities -4.40800M -2.95900M -1.55400M -4.23300M -4.28600M
Net borrowings -1.00500M 1.28M -0.17900M 0.45M 0.15M
Total cash from financing activities -1.00500M 1.28M -0.17900M 0.45M 0.15M
Change to operating activities 0.68M 0.52M -1.11800M 0.79M 0.18M
Net income -6.12200M 1.36M 1.00M -5.83800M 3.99M
Change in cash -4.99400M 1.94M -0.87300M 1.64M 1.17M
Begin period cash flow 7.29M 5.14M 6.01M 4.37M 3.20M
End period cash flow 2.30M 7.08M 5.14M 6.01M 4.37M
Total cash from operating activities 0.05M 3.29M 1.32M 5.38M 5.14M
Issuance of capital stock - - - - -
Depreciation 0.98M 1.13M 1.37M 1.48M 0.55M
Other cashflows from investing activities - - - - -
Dividends paid - - - - -
Change to inventory -0.98100M -0.03000M -0.84700M -1.03300M -0.23700M
Change to account receivables 1.51M -0.98700M -0.41500M 3.38M 0.47M
Sale purchase of stock - - - - -
Other cashflows from financing activities -0.14500M 3.83M -0.12100M 2.03M 0.88M
Change to netincome 3.37M 0.60M -0.04100M 8.01M -0.00200M
Capital expenditures 4.41M 2.96M 1.84M 4.23M 4.29M
Change receivables - - - - -
Cash flows other operating - - - - -
Exchange rate changes - - - - -
Cash and cash equivalents changes - - - - -
Change in working capital 0.53M -1.01700M -1.26200M 2.35M 0.40M
Stock based compensation - - - - -
Other non cash items 4.66M 1.81M 0.22M 7.39M -4.44400M
Free cash flow -4.35900M 0.33M -0.51900M 1.15M 0.85M

Fundamentals

  • Previous Close 0.26
  • Market Cap44.29M
  • Volume1023
  • P/E Ratio25.00
  • Dividend Yield-%
  • EBITDA2.79M
  • Revenue TTM50.13M
  • Revenue Per Share TTM0.31
  • Gross Profit TTM 22.11M
  • Diluted EPS TTM0.01

Peer Comparison

Sector: Healthcare Industry: Medical Devices

Company Change (AUD) Price (AUD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
CMP
Compumedics Ltd		 -0.01 3.85% 0.25 25.00 - 0.94 2.60 1.06 14.67
COH
Cochlear Ltd		 -0.88 0.28% 316.29 59.34 46.30 9.75 11.76 9.62 36.63
PNV
Polynovo Ltd		 -0.04 1.95% 2.01 - 140.85 17.37 21.49 17.51 647.42
AVR
Anteris Technologies Ltd		 -0.4 1.84% 21.30 - - 104.23 14.98 95.15 -5.9152
AVH
Avita Therapeutics Inc		 0.10 3.80% 2.73 - - 8.59 5.71 6.72 -10.0538

Reports Covered

Stock Research & News

View All

Profile

Compumedics Limited engages in the research, development, manufacturing, and distribution of medical equipment and related technologies in Australia, the Asia Pacific, the Americas, Europe, and the Middle East. It provides sleep diagnostics products, including Somfit/Somfit Pro, a wearable device for collecting patients' physiological data; Somté PSG; Okti; Grael PSG; Grael DC; Falcon HST; Somté, an investigative tool; and Somté PSG. The company also offers neurology diagnostics, such as ONsight A.V.S. for monitoring patient's home ambulatory studies; Grael 4K PSG:EEG amplifiers; Grael 4K-EEG amplifiers; Grael LT EEG System amplifiers; Neuvo 64-512 Channel LTM EEG monitoring systems; Okti, an portable EEG amplifier; and Siesta 802, a multi-functional ambulatory recording device. In addition, the company provides software products, such as Profusion Sleep software suite; Profusion EEG Software; Profusion neXus 360, a web-based patient data and lab management system that offers integrated hardware and software solutions for sleep and neurology clinics; Multi-Modal Neuroimaging Suite; Profusion neXus Laboratory Management System to optimize administrative and operational workflow needs of diagnostic and research laboratories; Profusion neXus Scheduler for planning for staff and time; and HD Digital Video, a plug-in software module to add synchronized digital video capabilities to sleep and EEG systems, as well as ECG Free, Profusion Plus, Siesta extended battery pack, summit IP, TCM5 FLEX transcutaneous monitors, and persyst software products. Further, it provides magnetoencephalography systems; brain research technologies; pharmaceutical clinical trials and research services; accessories; and consumables and supplies for diagnostic and research solutions. The company was incorporated in 1987 and is headquartered in Abbotsford, Australia. Compumedics Limited operates as a subsidiary of D & DJ Burton Holdings Pty Ltd.

Compumedics Ltd

30-40 Flockhart Street, Abbotsford, VIC, Australia, 3067

Key Executives

Name Title Year Born
Dr. David Burton Ph.D. Founder, Exec. Chairman, CEO & Member of Medical Advisory Board 1959
Mr. David Francis Lawson CFO, Company Sec. & Exec. Director 1965
Mr. Warwick Freeman Chief Technology Officer NA
Mr. Christoph Witte Gen. Managing of Director DWL Compumedics Germany GmbH NA
Dr. Kerry Trent Hubick Legal Counsel and Trademark, Patent & Gen. Legal Attorney NA
Dr. Curtis Ponton Chief Scientist of Neuroscan & VP NA
Mr. Paul Spooner Bus. Director of EMEA NA
Dr. David Burton Ph.D. Founder, Executive Chairman, CEO & Member of Medical Advisory Board 1959
Mr. David Francis Lawson CFO, Company Secretary & Executive Director 1965
Dr. Kerry Trent Hubick Legal Counsel and Trademark, Patent & General Legal Attorney NA

Disclaimer - Data Powered by EOD Historical Data (“EODHD”). All CFDs (stocks, indices, mutual funds, ETFs), and Forex are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. EODHD is not using exchanges data feeds for the pricing data, EODHD is using OTC, peer to peer trades and trading platforms over 100+ sources, EODHD is aggregating its data feeds via VWAP method. Therefore, EOD Historical Data doesn’t bear any responsibility for any trading losses you might incur as a result of using this data. EOD Historical Data or anyone involved with EOD Historical Data will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible. EOD Historical Data does not give any warranties (including, without limitation, as to merchantability or fitness for a particular purpose or use).

Our Company

Useful Links

Contact Us

Market Research

Our Company

Useful Links

Contact Us

Disclaimer

The information given by Kalkine Pty Ltd ABN34 154 808 312 (Australian Financial Services License Number 425376) on this website is general information or advice only.

It does not take into account any of your personal objectives, circumstances or needs. Choosing an investment is an important decision. If you do not feel confident making a decision based on the recommendations Kalkine has made in our reports, you should consider obtaining personal advice from an authorised adviser.

There may be a product disclosure statement or other offer document for the securities and financial products we write about in Kalkine Reports. You should obtain a copy of the product disclosure statement or offer document before making any decision about whether to acquire the security or product. Terms & Conditions have been provided for our services, please go through them and also read our Financial Services Guide.

Our website may contain information on past performance of particular investments. Past performance is not an indicator of future performance. Hypothetical returns may not reflect actual performance. Any displays of potential investment opportunities are for sample purposes only and may not actually be available to investors.

The information on the website does not constitute an offer to sell securities or a solicitation of an offer to buy securities. Our reports contain general recommendations to invest in securities.

Copyright 2024 Krish Capital Pty. Ltd. All rights reserved. No part of this website, or its content, may be reproduced in any form without our prior consent.